Vernal Keratoconjunctivitis Epidemiology Forecast

DelveInsight's 'Vernal Keratoconjunctivitis - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Vernal Keratoconjunctivitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.


Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
  • MEA (Saudi Arabia, Egypt, UAE)
  • China
  • Russia


Study Period: 2017-2030


Vernal Keratoconjunctivitis Understanding

Vernal keratoconjunctivitis (VKC) is a bilateral, usually seasonally recurrent, allergic inflammation of the conjunctiva, characterized by limbal gelatinous hypertrophy and/or upper tarsal giant conjunctival papillae. It is an IgE-mediated and T cell-mediated disease, leading to a chronic inflammation in which eosinophil, lymphocyte, and structural cell activation are involved. The disease may present in three clinical forms: tarsal, limbal and mixed form.


VKC mostly affects children and young adults living in warm climates worldwide. It begins typically in the first decade of life and resolves spontaneously after puberty even though in the most severe cases it can leave permanent lesions. It is characterized by intense itching, tearing, mucous secretions, and severe photophobia.


Vernal Keratoconjunctivitis Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Population of VKC, Diagnosed Prevalent Population of VKC, Gender-specific Diagnosed Prevalent Population of VKC, Type-specific Diagnosed Prevalent Population of VKC, Severity-specific Diagnosed Prevalent Population of VKC, and Age-specific Diagnosed Prevalent Population of VKC scenario of VKC in the global market from 2017 to 2030.

Vernal Keratoconjunctivitis Detailed Epidemiology Segmentation

  • The increasing population and rising prevalence of VKC generates a large patient population in the global market. In 2017, a total of 4,752,356 patients were affected by VKC in the global market.
  • China contributes the largest share among EU-5, and Japan, with 2,248,706 cases in 2017.
  • Egypt contributes the largest share among MEA regions, with 715,837 cases in 2017.
  • The total prevalent population of VKC in Russia was observed to be 859,969 cases in 2017.
  • The total diagnosed prevalent population of VKC was 2,943,057 in the global market.
  • The prevalence of VKC was observed more in males as compared to females. Out of the total prevalent population of 48,982 cases in the US for VKC, 41,634 cases and 7,347 cases were contributed by males and females, respectively.
  • Clinically, VKC can be divided into three subtypes: palpebral, bulbar, and mixed presentations. Disease severity seems milder in bulbar VKC, leading some to suspect that it is the early presentation of a spectrum of disease. Out of the total diagnosed cases of VKC in the US, 23,511 cases were of palpebral form, 21,552 cases were of bulbar form, and 3,919 cases were of mixed presentation.
  • Based on the severity, VKC is being categorized into three groups, i.e., mild, moderate, severe, and very severe. In 2017, mild, moderate, severe, and very severe diagnosed cases of VKC accounted for 17,584, 19,887, and 11,511 in the US.
  • DelveInsight’s epidemiology model for VKC estimates that out of the total diagnosed population of 48,982 cases in the US for VKC, 41,282 cases and 7,700 cases were contributed by children and adolescent (0–20 years), and adults (>20 years), respectively.


Scope of the Report

  • The Vernal Keratoconjunctivitis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Vernal Keratoconjunctivitis Epidemiology Report and Model provide an overview of the risk factors and global trends of Vernal Keratoconjunctivitis in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Vernal Keratoconjunctivitis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Vernal Keratoconjunctivitis
  • The report provides the segmentation of the Vernal Keratoconjunctivitis epidemiology


Report Highlights

  • 11-Year Forecast of VKC
  • Global Coverage
  • Total Prevalent Population of VKC
  • Diagnosed Prevalent Population of VKC
  • Gender-specific Diagnosed Prevalent Population of VKC
  • Type-specific Diagnosed Prevalent Population of VKC
  • Severity-specific Diagnosed Prevalent Population of VKC
  • Age-specific Diagnosed Prevalent Population of VKC


KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.


Key Questions Answered

  • What is the disease risk, burden and unmet needs of VKC?
  • What is the historical VKC patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), Japan, MEA (Saudi Arabia, Egypt, UAE), China, and Russia?
  • What would be the forecasted patient pool of VKC at the global level?
  • What will be the growth opportunities across the global market with respect to the patient population pertaining to VKC?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of VKC during the forecast period (2020–2030)?
  • At what CAGR the population is expected to grow across the global market during the forecast period (2020–2030)?


Reasons to buy

  • The Vernal Keratoconjunctivitis Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Vernal Keratoconjunctivitis market
  • Quantify patient populations in the global Vernal Keratoconjunctivitis market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Vernal Keratoconjunctivitis therapeutics in each of the markets covered
  • Understand the magnitude of Vernal Keratoconjunctivitis population by its epidemiology
  • The Vernal Keratoconjunctivitis Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources


Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Executive Summary of Vernal keratoconjunctivitis (VKC)

3. Vernal keratoconjunctivitis (VKC): Epidemiology Overview at a Glance

3.1. Total Epidemiological Share (%) Distribution of VKC in 2017

3.2. Total Epidemiological Share (%) Distribution of VKC in 2030

4. Disease Background and Overview: Vernal keratoconjunctivitis (VKC)

4.1. Introduction

4.2. Signs and Symptoms of VKC

4.2.1. Signs

4.3. Causes

4.4. Risk Factors

4.5. Grades of VKC

4.6. Pathophysiology

4.6.1. Mediators in VKC

4.6.2. Cells in VKC

4.7. Histopathology

4.8. Diagnosis of VKC

5. Case Reports

5.1. Vernal Keratoconjunctivitis: A Teaching Case Report

5.2. Ocular surface disease: A case of vernal keratoconjunctivitis

5.3. Topical and Oral Cyclosporine for a Case of Severe Limbal Vernal Keratoconjunctivitis with Complete Corneal Involvement

5.4. Severe vernal keratoconjunctivitis successfully treated with subcutaneous omalizumab

5.5. Recalcitrant Atopic Keratoconjunctivitis in Children: A Case Report and Literature Review

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Epidemiology Methodology

7. United States Epidemiology

7.1. Assumptions and Rationale

7.2. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in the United States

7.3. Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United States

7.4. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United States

7.5. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) Based on Symptoms in the United States

7.6. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United States

7.7. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United States

8. EU5 Epidemiology

8.1. Assumptions and Rationale

8.2. Germany Epidemiology

8.2.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Germany

8.2.2. Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Germany

8.2.3. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Germany

8.2.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) Based on Symptoms in Germany

8.2.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Germany

8.2.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Germany

8.3. France Epidemiology

8.3.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in France

8.3.2. Diagnosed Prevalent Population of Vernal Keratoconjunctivitis (VKC) in France

8.3.3. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in France

8.3.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in France

8.3.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in France

8.3.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in France

8.4. Italy Epidemiology

8.4.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Italy

8.4.2. Diagnosed Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Italy

8.4.3. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Italy

8.4.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Italy

8.4.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Italy

8.4.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Italy

8.5. Spain Epidemiology

8.5.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Spain

8.5.2. Diagnosed Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Spain

8.5.3. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Spain

8.5.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Spain

8.5.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Spain

8.5.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Spain

8.6. United Kingdom Epidemiology

8.6.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in the UK

8.6.2. Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the UK

8.6.3. Gender-specific Prevalence of Vernal Keratoconjunctivitis (VKC) in the UK

8.6.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United Kingdom

8.6.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United Kingdom

8.6.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United Kingdom

9. Japan Epidemiology

9.1.1. Assumptions and Rationale

9.1.2. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Japan

9.1.3. Diagnosed Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Japan

9.1.4. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Japan

9.1.5. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Japan

9.1.6. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Japan

9.1.7. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Japan

10. MEA Region Epidemiology

10.1. Assumptions and Rationale

10.2.Saudi Arabia Epidemiology

10.2.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Saudi Arabia

10.2.2. Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Saudi Arabia

10.2.3. Gender-specific Prevalence of Vernal Keratoconjunctivitis (VKC) in Saudi Arabia

10.2.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Saudi Arabia

10.2.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Saudi Arabia

10.2.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Saudi Arabia

10.3.Egypt Epidemiology

10.3.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Egypt

10.3.2. Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt

10.3.3. Gender-specific Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt

10.3.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt

10.3.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt

10.3.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt

10.4.UAE Epidemiology

10.4.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in UAE

10.4.2. Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in UAE

10.4.3. Gender-specific Prevalence of Vernal Keratoconjunctivitis (VKC) in UAE

10.4.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in UAE

10.4.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in UAE

10.4.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in UAE

11. China Epidemiology

11.1. Assumptions and Rationale

11.2. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in China

11.3. Diagnosed Prevalent Population of Vernal Keratoconjunctivitis (VKC) in China

11.4. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in China

11.5. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in China

11.6. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in China

11.7. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in China

12. Russia Epidemiology

12.1. Assumptions and Rationale

12.2. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Russia

12.3. Diagnosed Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Russia

12.4. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Russia

12.5. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Russia

12.6. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Russia

12.7. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Russia

13. KOL Views

14. Appendix

14.1. Bibliography

14.2. Report Methodology

15. DelveInsight Capabilities

16. Disclaimer

17. About DelveInsight

List Of Tables:

Table 1 : Summary of Vernal Keratoconjunctivitis (VKC), Epidemiology and Key Events (2017–2030)

Table 2 : Clinical grading (from 0 to 5) of vernal keratoconjunctivitis

Table 3 : Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in the US (2017–2030)

Table 4 : Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the US (2017–2030)

Table 5 : Gender-specific Diagnosed Prevalence of VKC in the US (2017–2030)

Table 6 : Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the US (2017–2030)

Table 7 : Severity-specific Diagnosed Prevalence of VKC in the US (2017–2030)

Table 8 : Age-specific Diagnosed Prevalence of VKC in the US (2017–2030)

Table 9 : Total Prevalent Population of VKC in Germany (2017–2030)

Table 10 : Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Germany (2017–2030)

Table 11 : Gender-Specific Diagnosed Prevalence of VKC in Germany (2017–2030)

Table 12 : Type-specific Diagnosed Prevalence of VKC in Germany (2017–2030)

Table 13 : Severity-specific Diagnosed Prevalence of VKC in Germany (2017–2030)

Table 14 : Age-specific Diagnosed Prevalence of VKC in Germany (2017–2030)

Table 15 : Total Prevalent Population of VKC in France (2017–2030)

Table 16 : Diagnosed Prevalent Population of VKC in France (2017–2030)

Table 17 : Gender-specific Diagnosed Prevalence of VKC in France (2017–2030)

Table 18 : Type-specific Diagnosed Prevalence of VKC in France (2017–2030)

Table 19 : Severity-specific Diagnosed Prevalence of VKC in France (2017–2030)

Table 20 : Age-specific Diagnosed Prevalence of VKC in France (2017–2030)

Table 21 : Total Prevalent Population of VKC in Italy (2017–2030)

Table 22 : Diagnosed Prevalent Population of VKC in Italy (2017–2030)

Table 23 : Gender-specific Diagnosed Prevalence of VKC in Italy (2017–2030)

Table 24 : Type-specific Diagnosed Prevalence of VKC in Italy (2017–2030)

Table 25 : Severity-specific Diagnosed Prevalence of VKC in Italy (2017–2030)

Table 26 : Age-specific Diagnosed Prevalence of VKC in Italy (2017–2030)

Table 27 : Total Prevalent Population of VKC in Spain (2017–2030)

Table 28 : Diagnosed Prevalent Population of VKC in Spain (2017–2030)

Table 29 : Gender-specific Diagnosed Prevalence of VKC in Spain (2017–2030)

Table 30 : Type-specific Diagnosed Prevalence of VKC in Spain (2017–2030)

Table 31 : Severity-specific Diagnosed Prevalence of VKC in Spain (2017–2030)

Table 32 : Age-specific Diagnosed Prevalence of VKC in Spain (2017–2030)

Table 33 : Total Prevalent Population of VKC in the UK (2017–2030)

Table 34 : Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the UK (2017–2030)

Table 35 : Gender-Specific Prevalence of Vernal Keratoconjunctivitis (VKC) in the UK (2017–2030)

Table 36 : Type-specific Diagnosed Prevalence of VKC in the United Kingdom (2017–2030)

Table 37 : Severity-specific Diagnosed Prevalence of VKC in the United Kingdom (2017–2030)

Table 38 : Age-specific Diagnosed Prevalence of VKC in the UK (2017–2030)

Table 39 : Total Prevalent Population of VKC in Japan (2017–2030)

Table 40 : Diagnosed Prevalent Population of VKC in Japan (2017–2030)

Table 41 : Gender-specific Diagnosed Prevalence of VKC in Japan (2017–2030)

Table 42 : Type-specific Diagnosed Prevalence of VKC in Japan (2017–2030)

Table 43 : Severity-specific Diagnosed Prevalence of VKC in Japan (2017–2030)

Table 44 : Age-specific Diagnosed Prevalence of VKC in Japan (2017–2030)

Table 45 : Total Prevalent Population of VKC in Saudi Arabia (2017–2030)

Table 46 : Diagnosed Prevalence of VKC in Saudi Arabia (2017–2030)

Table 47 : Gender-Specific Prevalence of VKC in Saudi Arabia (2017–2030)

Table 48 : Type-specific Diagnosed Prevalence of VKC in Saudi Arabia (2017–2030)

Table 49 : Severity-specific Diagnosed Prevalence of VKC in Saudi Arabia (2017–2030)

Table 50 : Age-specific Diagnosed Prevalence of VKC in Saudi Arabia (2017–2030)

Table 51 : Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Egypt (2017–2030)

Table 52 : Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt (2017–2030)

Table 53 : Gender-Specific Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt (2017–2030)

Table 54 : Type-specific Diagnosed Prevalence of VKC in Egypt (2017–2030)

Table 55 : Severity-specific Diagnosed Prevalence of VKC in Egypt (2017–2030)

Table 56 : Age-specific Diagnosed Prevalence of VKC in Egypt (2017–2030)

Table 57 : Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in UAE (2017–2030)

Table 58 : Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in UAE (2017–2030)

Table 59 : Gender-Specific Prevalence of Vernal Keratoconjunctivitis (VKC) in UAE (2017–2030)

Table 60 : Type-specific Diagnosed Prevalence of VKC in UAE (2017–2030)

Table 61 : Severity-specific Diagnosed Prevalence of VKC in UAE (2017–2030)

Table 62 : Age-specific Diagnosed Prevalence of VKC in UAE (2017–2030)

Table 63 : Total Prevalent Population of VKC in China (2017–2030)

Table 64 : Diagnosed Prevalent Population of VKC in China (2017–2030)

Table 65 : Gender-specific Diagnosed Prevalence of VKC in China (2017–2030)

Table 66 : Type-specific Diagnosed Prevalence of VKC in China (2017–2030)

Table 67 : Severity-specific Diagnosed Prevalence of VKC in China (2017–2030)

Table 68 : Age-specific Diagnosed Prevalence of VKC in China (2017–2030)

Table 69 : Total Prevalent Population of VKC in Russia (2017–2030)

Table 70 : Diagnosed Prevalent Population of VKC in Russia (2017–2030)

Table 71 : Gender-specific Diagnosed Prevalence of VKC in Russia (2017–2030)

Table 72 : Type-specific Diagnosed Prevalence of VKC in Russia (2017–2030)

Table 73 : Severity-specific Diagnosed Prevalence of VKC in Russia (2017–2030)

Table 74 : Age-specific Diagnosed Prevalence of VKC in Russia (2017–2030)


List of Figures:

Figure 1 : Anatomy and symptoms of vernal keratoconjunctivitis

Figure 2 : Common symptoms of VKC

Figure 3 : Clinical sign of vernal keratoconjunctivitis

Figure 4 : Risk factors of VKC

Figure 5 : Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in the US (2017–2030)

Figure 6 : Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the US (2017–2030)

Figure 7 : Gender-Specific Diagnosed Prevalence of VKC in the US (2017–2030)

Figure 8 : Type-specific Diagnosed Prevalence of VKC in the US (2017–2030)

Figure 9 : Severity-specific Diagnosed Prevalence of VKC in the US (2017–2030)

Figure 10 : Age-specific Diagnosed Prevalence of VKC in the US (2017–2030)

Figure 11 : Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Germany (2017–2030)

Figure 12 : Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Germany (2017–2030)

Figure 13 : Gender-Specific Diagnosed Prevalence of VKC in Germany (2017–2030)

Figure 14 : Type-specific Diagnosed Prevalence of VKC in Germany (2017–2030)

Figure 15 : Severity-specific Diagnosed Prevalence of VKC in Germany (2017–2030)

Figure 16 : Age-specific Diagnosed Prevalence of VKC in Germany (2017–2030)

Figure 17 : Total Prevalent Population of VKC in France (2017–2030)

Figure 18 : Diagnosed Prevalent Population of VKC in France (2017–2030)

Figure 19 : Gender-specific Diagnosed Prevalence of VKC in France (2017–2030)

Figure 20 : Type-specific Diagnosed Prevalence of VKC in France (2017–2030)

Figure 21 : Severity-specific Diagnosed Prevalence of VKC in France (2017–2030)

Figure 22 : Age-specific Diagnosed Prevalence of VKC in France (2017–2030)

Figure 23 : Total Prevalent Population of VKC in Italy (2017–2030)

Figure 24 : Diagnosed Prevalent Population of VKC in Italy (2017–2030)

Figure 25 : Gender-specific Diagnosed Prevalence of VKC in Italy (2017–2030)

Figure 26 : Type-specific Diagnosed Prevalence of VKC in Italy (2017–2030)

Figure 27 : Severity-specific Diagnosed Prevalence of VKC in Italy (2017–2030)

Figure 28 : Age-specific Diagnosed Prevalence of VKC in Italy (2017–2030)

Figure 29 : Total Prevalent Population of VKC in Spain (2017–2030)

Figure 30 : Diagnosed Prevalent Population of VKC in Spain (2017–2030)

Figure 31 : Gender-specific Diagnosed Prevalence of VKC in Spain (2017–2030)

Figure 32 : Type-specific Diagnosed Prevalence of VKC in Spain (2017–2030)

Figure 33 : Severity-specific Diagnosed Prevalence of VKC in Spain (2017–2030)

Figure 34 : Age-specific Diagnosed Prevalence of VKC in Spain (2017–2030)

Figure 35 : Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in the UK (2017–2030)

Figure 36 : Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the UK (2017–2030)

Figure 37 : Gender-Specific Prevalence of Vernal Keratoconjunctivitis (VKC) in the UK (2017–2030)

Figure 38 : Type-specific Diagnosed Prevalence of VKC in the United Kingdom (2017–2030)

Figure 39 : Severity-specific Diagnosed Prevalence of VKC in the United Kingdom (2017–2030)

Figure 40 : Age-specific Diagnosed Prevalence of VKC in the UK (2017–2030)

Figure 41 : Total Prevalent Population of VKC in Japan (2017–2030)

Figure 42 : Diagnosed Prevalent Population of VKC in Japan (2017–2030)

Figure 43 : Gender-specific Diagnosed Prevalence of VKC in Japan (2017–2030)

Figure 44 : Type-specific Diagnosed Prevalence of VKC in Japan (2017–2030)

Figure 45 : Severity-specific Diagnosed Prevalence of VKC in Japan (2017–2030)

Figure 46 : Age-specific Diagnosed Prevalence of VKC in Japan (2017–2030)

Figure 47 : Total Prevalent Population of VKC in Saudi Arabia (2017–2030)

Figure 48 : Diagnosed Prevalence of VKC in Saudi Arabia (2017–2030)

Figure 49 : Gender-Specific Prevalence of VKC in Saudi Arabia (2017–2030)

Figure 50 : Type-specific Diagnosed Prevalence of VKC in Saudi Arabia (2017–2030)

Figure 51 : Severity-specific Diagnosed Prevalence of VKC in Saudi Arabia (2017–2030)

Figure 52 : Age-specific Diagnosed Prevalence of VKC in Saudi Arabia (2017–2030)

Figure 53 : Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Egypt (2017–2030)

Figure 54 : Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt (2017–2030)

Figure 55 : Gender-Specific Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt (2017–2030)

Figure 56 : Type-specific Diagnosed Prevalence of VKC in Egypt (2017–2030)

Figure 57 : Severity-specific Diagnosed Prevalence of VKC in Egypt (2017–2030)

Figure 58 : Age-specific Diagnosed Prevalence of VKC in Egypt (2017–2030)

Figure 59 : Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in UAE (2017–2030)

Figure 60 : Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in UAE (2017–2030)

Figure 61 : Gender-Specific Prevalence of Vernal Keratoconjunctivitis (VKC) in UAE (2017–2030)

Figure 62 : Type-specific Diagnosed Prevalence of VKC in UAE (2017–2030)

Figure 63 : Severity-specific Diagnosed Prevalence of VKC in UAE (2017–2030)

Figure 64 : Age-specific Diagnosed Prevalence of VKC in UAE (2017–2030)

Figure 65 : Total Prevalent Population of VKC in China (2017–2030)

Figure 66 : Diagnosed Prevalent Population of VKC in China (2017–2030)

Figure 67 : Gender-specific Diagnosed Prevalence of VKC in China (2017–2030)

Figure 68 : Type-specific Diagnosed Prevalence of VKC in China (2017–2030)

Figure 69 : Severity-specific Diagnosed Prevalence of VKC in China (2017–2030)

Figure 70 : Age-specific Diagnosed Prevalence of VKC in China (2017–2030)

Figure 71 : Total Prevalent Population of VKC in Russia (2017–2030)

Figure 72 : Diagnosed Prevalent Population of VKC in Russia (2017–2030)

Figure 73 : Gender-specific Diagnosed Prevalence of VKC in Russia (2017–2030)

Figure 74 : Type-specific Diagnosed Prevalence of VKC in Russia (2017–2030)

Figure 75 : Severity-specific Diagnosed Prevalence of VKC in Russia (2017–2030)

Figure 76 : Age-specific Diagnosed Prevalence of VKC in Russia (2017–2030)


  • Tags:
  • Vernal Keratoconjunctivitis Epidemi...
  • Vernal Keratoconjunctivitis
  • Vernal Keratoconjunctivitis Pipeli...
  • Vernal Keratoconjunctivitis Compan...
  • Vernal Keratoconjunctivitis preval...
  • Vernal Keratoconjunctivitis incide...
  • Vernal Keratoconjunctivitis patien...
  • Vernal Keratoconjunctivitis treatm...

Forward to Friend

Need A Quote